Company profile
NEKTAR THERAPEUTICS
NASDAQ:NKTRBiotechnology: Pharmaceutical Preparations
Drug pipeline (4)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ETIRINOTECAN PEGOL | phase3 | — | 7 | no active trials |
| REZPEGALDESLEUKIN | phase3 | — | 13 | active |
| OXYCODEGOL | phase2 | — | 2 | completed, terminated |
| BEMPEGALDESLEUKIN | phase1_2 | — | 13 | completed, terminated, withdrawn |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (39)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04955262 | phase1 | withdrawn | 2019-08-01 | 2021-06-01 | Nektar Therapeutics | A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab |
| NCT02983045 | phase1_2 | completed | 2016-12-19 | 2022-04-28 | Nektar Therapeutics | A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors |
| NCT02869295 | phase1_2 | completed | 2015-12-01 | 2018-10-31 | Nektar Therapeutics | A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors |
| NCT01619839 | phase2 | completed | 2012-06-01 | 2013-08-01 | Nektar Therapeutics | A Phase 2 Study To Assess The Efficacy, Tolerability, And Safety OF NKTR-181 In Subjects With Chronic OA Knee Pain |
| NCT06136741 | phase2 | active_not_recruiting | 2023-11-15 | 2025-05-06 | Nektar Therapeutics | A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis |
FDA applications (0)
No records yet.